E
Eduardo R. Pajon
Researcher at MedStar Washington Hospital Center
Publications - 18
Citations - 3908
Eduardo R. Pajon is an academic researcher from MedStar Washington Hospital Center. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 14, co-authored 18 publications receiving 3599 citations. Previous affiliations of Eduardo R. Pajon include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi,Stewart J. Anderson,Harry D. Bear,Charles E. Geyer,Morton S. Kahlenberg,André Robidoux,Richard G. Margolese,James L. Hoehn,Victor G. Vogel,Shaker R. Dakhil,Deimante Tamkus,Karen M. King,Eduardo R. Pajon,Mary Johanna Wright,Jean Robert,Soonmyung Paik,Eleftherios P. Mamounas,Norman Wolmark +17 more
TL;DR: B-18 and B-27 demonstrate that preoperative therapy is equivalent to adjuvant therapy and showed that the addition of preoperative taxanes to AC improves response.
Journal ArticleDOI
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Victor G. Vogel,Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,Eduardo R. Pajon,James L. Wade,André Robidoux,Richard G. Margolese,Joan James,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Worta McCaskill-Stevens,Leslie G. Ford,V. Craig Jordan,Norman Wolmark +20 more
TL;DR: Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxfene in preventing noninvasive disease, with far less toxicity.
Journal ArticleDOI
Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial
Eleftherios P. Mamounas,Jong-Hyeon Jeong,D. Lawrence Wickerham,Roy E. Smith,Patricia A. Ganz,Stephanie R. Land,Andrea Eisen,Louis Fehrenbacher,William B. Farrar,James N. Atkins,Eduardo R. Pajon,Victor G. Vogel,Joan Kroener,Laura F. Hutchins,André Robidoux,James L. Hoehn,James N. Ingle,Charles E. Geyer,Joseph P. Costantino,Norman Wolmark +19 more
TL;DR: Original exemestane assignment resulted in non-statistically significant improvement in DFS and in statisticallysignificant improvement in RFS, and toxicity, assessed up to time of unblinding, was acceptable for the adjuvant setting.
Journal ArticleDOI
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
Sandra M. Swain,Jong-Hyeon Jeong,Charles E. Geyer,Charles E. Geyer,Joseph P. Costantino,Eduardo R. Pajon,Louis Fehrenbacher,Louis Fehrenbacher,James N. Atkins,Jonathan Polikoff,Jonathan Polikoff,Victor G. Vogel,Victor G. Vogel,Victor G. Vogel,John K. Erban,John K. Erban,Priya Rastogi,Priya Rastogi,Robert B. Livingston,Edith A. Perez,Eleftherios P. Mamounas,Stephanie R. Land,Stephanie R. Land,Patricia A. Ganz,Patricia A. Ganz,Norman Wolmark,Norman Wolmark +26 more
TL;DR: Overall survival was improved in patients with amenorrhea for 6 months or more across all treatment groups, independently of estrogen-receptor status, and Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it improved overall survival.
Journal ArticleDOI
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Victor G. Vogel,Joseph P. Costantino,D. Lawrence Wickerham,Walter M. Cronin,Reena S. Cecchini,James N. Atkins,Therese B. Bevers,Louis Fehrenbacher,Eduardo R. Pajon,James L. Wade,Andr Robidoux,Richard G. Margolese,Joan James,Scott M. Lippman,Carolyn D. Runowicz,Patricia A. Ganz,Steven E. Reis,Worta McCaskill-Stevens,Leslie C. Ford,V. Craig Jordan,Norman Wolmark +20 more
TL;DR: There was no difference in total deaths, and causes of death were similarly distributed in the 2 groups, and no group differences were documented for invasive cancer at other sites, ischemic heart disease events, or strokes.